Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Recruiting
Phase 1
Phase 2
Interventional Study
B-cell Acute Lymphoblastic Leukemia
Large B-cell Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Marginal Zone Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma
Burkitt Lymphoma
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Non Hodgkin Lymphoma
Mixed Phenotype Acute Leukemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 13 – 90
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 32 (estimated)
- Sponsor
- Vironexis Biotherapeutics Inc. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age: Part 1: 18-90 years of age, Part 2: 13-90 years of age
* Relapsed or refractory CD-19 positive leukemia or lymphoma as defined in the protocol
* CD19-positive expression
* AAV specified capsid total antibody \<1:400
* Protocol-specified ranges for renal, liver, cardiac an…
Contacts